
|Videos|January 6, 2014
Chemotherapy-Related Adverse Events Versus Immunotherapy-Related Adverse Events
Author(s)Matthew Burke, MBA, RN, MSN, APRN-BC
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Advertisement
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Clinical Pearls:
- Chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body
- Immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent
- Because the immune system is altered during treatment, the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events
- It is currently difficult to predict which patients will experience severe adverse events from immunotherapy treatment
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5








































